Alexion Pharm Inc (ALXN) 133.50 $ALXN
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 3.06% Rise
Comtex SmarTrend(R) - 2 hrs ago
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.76 to a high of $135.14. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $135.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
After Yesterday's Rally of 1.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:10PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.00 to a high of $135.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $130.32 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 12.97 (+0.10), ANIP: 60.85 (+0.25), ALXN: 133.50 (+4.90), NKTR: 17.75 (+0.46)
Alexion (ALXN) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
Alexion (ALXN) reported earnings of 92 cents in the second-quarter of 2016, with revenues coming in at $753 million.
ALXN: 133.50 (+4.90)
Alexion Reports Second Quarter 2016 Results
BusinessWire - Thu Jul 28, 5:30AM CDT
--- Soliris(R) (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
ALXN: 133.50 (+4.90)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.85 (+11.92), VRTX: 98.21 (+1.21), GILD: 80.39 (+0.92), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), ABBV: 66.88 (+0.65), CELG: 114.15 (+1.96)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.64 (+0.09), BIIB: 301.85 (+11.92), ABT: 45.34 (+0.59), JNJ: 125.42 (+0.19), GILD: 80.39 (+0.92), ALXN: 133.50 (+4.90), ARIA: 9.69 (+0.18), BMY: 76.24 (+1.43), CELG: 114.15 (+1.96), NVS: 83.19 (-0.07)
Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 125.25 (+4.24), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), BMY: 76.24 (+1.43)
Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 2:17PM CDT
Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
BIIB: 301.85 (+11.92), GILD: 80.39 (+0.92), CYTR: 0.59 (-0.06), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), ABBV: 66.88 (+0.65), JUNO: 30.60 (-0.33)
Upgrade Alert for Alexion Pharmaceuticals (ALXN)
Comtex SmarTrend(R) - Tue Jul 12, 3:34AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $125.30 on volume of 1.7 million shares, above average daily volume of 1.6 million. In the past 52 weeks, Alexion Pharmaceuticals share prices have been bracketed by a low of $110.56 and a high of $208.88 and closed yesterday at $125.30, 13% above that low price. In the last five trading sessions, the 50-day moving average (MA) has remained constant while the 200-day MA has slid 0.8%.
ALXN: 133.50 (+4.90)
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 1.27% Rise
Comtex SmarTrend(R) - Mon Jul 11, 2:42PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.01 to a high of $126.39. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $125.54 on volume of 476,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.00 (+0.01), BIIB: 301.85 (+11.92), VRTX: 98.21 (+1.21), GILD: 80.39 (+0.92), UNH: 143.47 (+0.27), MRK: 58.79 (+0.13), ALXN: 133.50 (+4.90), XOM: 85.99 (-2.96), CVX: 99.02 (-3.46), REGN: 435.73 (+10.61), CELG: 114.15 (+1.96)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.91%
Comtex SmarTrend(R) - Wed Jul 06, 12:34PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $116.40 to a high of $121.63. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $119.76 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 17, 8:30PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
ALXN: 133.50 (+4.90)
Alexion Pharmaceuticals Falls 1.62% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 17, 12:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.80 to a high of $127.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $127.20 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 133.50 (+4.90)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 253.78 (+0.83), BIIB: 301.85 (+11.92), MDT: 88.11 (+0.48), ALXN: 133.50 (+4.90), XOM: 85.99 (-2.96), BMY: 76.24 (+1.43), CVX: 99.02 (-3.46)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 301.85 (+11.92), BMRN: 99.85 (+0.43), ALXN: 133.50 (+4.90), IBB: 293.83 (+4.39), REGN: 435.73 (+10.61)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.85 (+11.92), BMRN: 99.85 (+0.43), SRPT: 25.79 (+0.51), ALXN: 133.50 (+4.90), IBB: 293.83 (+4.39), REGN: 435.73 (+10.61)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 133.50 (+4.90)
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 3.06% Rise
Comtex SmarTrend(R) - 2 hrs ago
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.76 to a high of $135.14. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $135.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
After Yesterday's Rally of 1.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:10PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.00 to a high of $135.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $130.32 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 12.97 (+0.10), ANIP: 60.85 (+0.25), ALXN: 133.50 (+4.90), NKTR: 17.75 (+0.46)
Alexion (ALXN) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
Alexion (ALXN) reported earnings of 92 cents in the second-quarter of 2016, with revenues coming in at $753 million.
ALXN: 133.50 (+4.90)
Alexion Reports Second Quarter 2016 Results
BusinessWire - Thu Jul 28, 5:30AM CDT
--- Soliris(R) (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
ALXN: 133.50 (+4.90)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.85 (+11.92), VRTX: 98.21 (+1.21), GILD: 80.39 (+0.92), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), ABBV: 66.88 (+0.65), CELG: 114.15 (+1.96)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.64 (+0.09), BIIB: 301.85 (+11.92), ABT: 45.34 (+0.59), JNJ: 125.42 (+0.19), GILD: 80.39 (+0.92), ALXN: 133.50 (+4.90), ARIA: 9.69 (+0.18), BMY: 76.24 (+1.43), CELG: 114.15 (+1.96), NVS: 83.19 (-0.07)
Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 125.25 (+4.24), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), BMY: 76.24 (+1.43)
Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 2:17PM CDT
Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
BIIB: 301.85 (+11.92), GILD: 80.39 (+0.92), CYTR: 0.59 (-0.06), ALXN: 133.50 (+4.90), AMGN: 174.17 (+2.14), ABBV: 66.88 (+0.65), JUNO: 30.60 (-0.33)
Upgrade Alert for Alexion Pharmaceuticals (ALXN)
Comtex SmarTrend(R) - Tue Jul 12, 3:34AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $125.30 on volume of 1.7 million shares, above average daily volume of 1.6 million. In the past 52 weeks, Alexion Pharmaceuticals share prices have been bracketed by a low of $110.56 and a high of $208.88 and closed yesterday at $125.30, 13% above that low price. In the last five trading sessions, the 50-day moving average (MA) has remained constant while the 200-day MA has slid 0.8%.
ALXN: 133.50 (+4.90)
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 1.27% Rise
Comtex SmarTrend(R) - Mon Jul 11, 2:42PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.01 to a high of $126.39. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $125.54 on volume of 476,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.00 (+0.01), BIIB: 301.85 (+11.92), VRTX: 98.21 (+1.21), GILD: 80.39 (+0.92), UNH: 143.47 (+0.27), MRK: 58.79 (+0.13), ALXN: 133.50 (+4.90), XOM: 85.99 (-2.96), CVX: 99.02 (-3.46), REGN: 435.73 (+10.61), CELG: 114.15 (+1.96)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.91%
Comtex SmarTrend(R) - Wed Jul 06, 12:34PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $116.40 to a high of $121.63. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $119.76 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 133.50 (+4.90)
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 17, 8:30PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. ALXN: 133.50 (+4.90)
Alexion Pharmaceuticals Falls 1.62% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 17, 12:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.80 to a high of $127.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $127.20 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 133.50 (+4.90)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 253.78 (+0.83), BIIB: 301.85 (+11.92), MDT: 88.11 (+0.48), ALXN: 133.50 (+4.90), XOM: 85.99 (-2.96), BMY: 76.24 (+1.43), CVX: 99.02 (-3.46)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 301.85 (+11.92), BMRN: 99.85 (+0.43), ALXN: 133.50 (+4.90), IBB: 293.83 (+4.39), REGN: 435.73 (+10.61)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.85 (+11.92), BMRN: 99.85 (+0.43), SRPT: 25.79 (+0.51), ALXN: 133.50 (+4.90), IBB: 293.83 (+4.39), REGN: 435.73 (+10.61)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 133.50 (+4.90)
